EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK2V617F ‐dependent down regulation of SHP ‐1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF ‐β

Céline Aoun, Nabih Maslah, Saravanan Ganesan, Norman Salomao, Romane Gendron, Sarah Awan Toor, Gil Letort, Panhong Gou, Mélina Bonnamy, Véronique Parietti, Jean-Jacques Kiladjian, Stephane Giraudier und 1 weitere

Journal of Cellular and Molecular Medicine · 2024-10 · 28 (20)

DOI: 10.1111/jcmm.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 21.10.2024. Verfasst von Céline Aoun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMRS_1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France. Hauptthemen laut MEDLINE: Janus Kinase 2, Transforming Growth Factor beta, Myeloproliferative Disorders, Cell Proliferation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation ARC pour la Recherche sur le Cancer, Fondation Leucemie Espoir, Institut National Du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are characterized by an increased production of blood cells due to the acquisition of mutations such as JAK2 V617F . TGF‐β, whose secretion is increased in MPN patients, is known to negatively regulate haematopoietic stem cell (HSC) proliferation. Using an isogenic JAK2 V617F or JAK2 wild‐type UT‐7 cell line we observed that JAK2 V617F cells resist to TGF‐β antiproliferative activity. Although TGF‐β receptors and SMAD2/3 expressions are similar in both cell types, TGF‐β‐induced phosphorylation of SMAD2/3 is reduced in UT‐7 JAK2 V617F cells compared with JAK2 WT cells. We confirmed that JAK2 V617F mutated cells are resistant to the antiproliferative effect of TGF‐β in a competitive assay as we observed a positive selection of JAK2 V617F cells when exposed to TGF‐β. Using cell lines, CD34‐positive cells from MPN patients and bone marrow cells from JAK2 V617F knock‐in mice we identified a down regulation of the SHP‐1 phosphatase, which is required for the regulation of HSC quiescence by TGF‐β. The transduction of SHP‐1 cDNA (but not a phosphatase inactive cDNA) restores the antiproliferative effect of TGF‐β in JAK2 V617F mutated cells. Finally, SC‐1, a known agonist of SHP‐1, antagonized the selection of JAK2 V617F mutated cells in the presence of TGF‐β. In conclusion, we show a JAK2‐dependent down regulation of SHP‐1 in MPN patients' cells which is related to their resistance to the antiproliferative effect of TGF‐β. This may participate in the clonal selection of cancer cells in MPNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Transforming Growth Factor betaMyeloproliferative DisordersCell ProliferationProtein Tyrosine Phosphatase, Non-Receptor Type 6HumansAnimalsMiceCell Line, TumorHematopoietic Stem CellsDown-RegulationPhosphorylationSmad2 ProteinMutation

Stichwörter der Autor:innen

JAK2Myeloproliferative neoplasmsSHP‐1TGF‐β

Substanzen

Janus Kinase 2Transforming Growth Factor betaProtein Tyrosine Phosphatase, Non-Receptor Type 6JAK2 protein, humanSmad2 Protein

Autor:innen und Institutionen

  • Inserm UMRS_1131, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
  • Laboratoire de Biologie Cellulaire, APHP, Hopital Saint-Louis, Paris, France.
  • Université Paris Cité, INSERM/CNRS, US53/UAR2030, Institut de Recherche Saint-Louis, Paris, France.
  • Centre d'Investigations Cliniques, APHP, Hopital Saint-Louis, Paris, France.

ORCID-Profile: Bruno Cassinat

Förderung

  • Fondation ARC pour la Recherche sur le Cancer
  • Fondation Leucemie Espoir
  • Institut National Du Cancer

Zitieren

APA

Aoun, C., Maslah, N., Ganesan, S., Salomao, N., Gendron, R., Awan Toor, S., Letort, G., Gou, P., Bonnamy, M., Parietti, V., Kiladjian, J. J., Giraudier, S., & Cassinat, B. (2024). JAK2V617F ‐dependent down regulation of SHP ‐1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF ‐β. Journal of Cellular and Molecular Medicine, 28(20). https://doi.org/10.1111/jcmm.70138

Vancouver

Aoun C, Maslah N, Ganesan S, Salomao N, Gendron R, Awan Toor S, et al. JAK2V617F ‐dependent down regulation of SHP ‐1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF ‐β. Journal of Cellular and Molecular Medicine. 2024;28(20). doi:10.1111/jcmm.70138

BibTeX
@article{Aoun2024,
  author = {Aoun, Céline and Maslah, Nabih and Ganesan, Saravanan and Salomao, Norman and Gendron, Romane and Awan Toor, Sarah and Letort, Gil and Gou, Panhong and Bonnamy, Mélina and Parietti, Véronique and Kiladjian, Jean-Jacques and Giraudier, Stephane and Cassinat, Bruno},
  title = {JAK2V617F ‐dependent down regulation of SHP ‐1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF ‐β},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  volume = {28},
  number = {20},
  doi = {10.1111/jcmm.70138}
}
Kostenlos starten →